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Background: Drug-eluting stents (DES) were initially used 'on-label' in simple
lesions and low-risk patients. Contemporary second-generation DES are more often
used in 'off-label' settings, while there is limited knowledge about the potential
increase in event risk.
Methods: We analyzed the 2-year clinical outcome data of 1387 TWENTE trial
patients treated with liberal off-label use of second-generation everolimus-eluting
Xience V or zotarolimus-eluting Resolute stents. Periprocedural myocardial infarction
(PMI) was deﬁned as myocardial infarction (MI) 48 hours following PCI. MI was
deﬁned as 2x the upper reference limit of creatine kinase (CK).
Results: Off-label patients (n¼1033; 74.5%) had more diabetes (22.9% vs. 17.5%;
p<0.05), previous MI (35.9% vs. 22.3%; p<0.05), complex lesions (76.1% vs.
60.7%; p<0.05), and acute coronary syndromes (57.8% vs. 33.3%; p<0.05). There
was a higher incidence of periprocedural MI in off-label patients (5.0% vs. 1.4%;
p<0.05), of whom merely 1.1% developed creatine kinase levels >5x ULN.
Consequently, target vessel-related MI was higher in off-label patients (6.4% vs.
2.8%; p<0.05). Nevertheless, cardiac death and target vessel revascularization rates
were similar for both groups (p>0.8).
Conclusions: Patients with off-label DES use had more periprocedural MI. Despite
a higher risk proﬁle and a higher rate of periprocedural MI, 2-year clinical outcome
did not differ from that of patients with on-label DES use. Our ﬁndings underline the
favorable safety proﬁle of these second-generation DES in off-label settings.TCT-343
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Background: The National Cardiovascular Data Registry (NCDR) bleeding risk score
model was derived from a predominantly Caucasian population, with an under-rep-
resented African American (AA) population of 6%. Differential post-PCI bleeding
rates have been reported. We aim to analyze the post-PCI bleeding rates in a better-
represented AA population.
Methods: From our own PCI registry, bleeding (deﬁned by NCDR CathPCI registry
as transfusion, prolonged hospital stay and/or drop in hemoglobin >3g/dL) rates were
compared between AA and non-AA patients. A logistic regression model was used to
compare the accuracy of the NCDR risk score in predicting post-PCI bleed in AA and
non-AA patients, and a net reclassiﬁcation improvement (NRI) analysis was used to
determine if the model's predictive ability was enhanced by adding AA race as
a variable.
Results: A total of 22438 PCI patients were evaluated, of which 6396 (28.5%) were
AA. Although NCDR bleeding risk score was higher in AA than in non-AA [median
(IQR) 13 (8-18) vs 11 (6-17), p <0.001], overall observed bleeding event rates were
similar (5.0% vs. 5.6%, p¼NS). Observed bleeding event rates across risk scores areJACC Vol 62/18S1/Suppl B j October 27–November 1, 2013 j TCT Abpresented in Figure 1. The NCDR model predicted post-PCI bleeding similarly in AA
and non-AA (AUC 0.68 vs 0.72, p¼0.09) (Figure 2), and the model's predictability
was not enhanced by adding AA race as a variable using NRI analysis (NRI 4.8%,
p¼0.20).
Conclusions: The predicted post-PCI bleeding risk was higher in AA compared to
non-AA; however, observed bleeding rates were similar. The NCDR bleeding risk
score remained predictive of post-PCI bleed in both groups.TCT-344
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Background: Contrast-induced nephropathy (CIN) is the third leading cause of acute
renal failure in hospitalized patients and has a negative prognostic impact with
increased mortality and hospital stay. The incidence of CIN in patients undergoing
primary percutaneous coronary intervention (PCI) is higher than in programmed
procedures. In primary PCIs, CIN prevention measures are less applied than in pro-
grammed PCIs. Aim: to analyze CIN in patients undergoing primary PCI and the role
of hydration in its prevention.
Methods: 204 patients (62.813.8 years; 73.5% male) with STEMI who underwent
primary PCI were randomly assigned to receive either hydration with normal saline:
1ml/kg/hour since the beginning of the procedure and 24 hours after it (SS group) or
not (NS group). CIN was deﬁned as a 25% or 0.5 mg/dL increase in serum creatinine
 within 48-72 hours following the procedure.
Results: 41.2% had hypertension, 23.4% diabetes mellitus, 13.3% renal dysfunction
and 15.9% anemia. Mean contrast volume used was 168  69 cc. There were no
signiﬁcant differences between the two groups regarding baseline features, apart from
the higher contrast volume used in the SS group (180 vs 157 cc; p¼0.023). 101
patients (49.5%) were included in SS group and 103 (50.5%) in NS group. We per-
formed an intention to treat analysis with 26% of crossover between groups. CIN was
observed in 17 patients (8.7%): 13 in the NS group and 4 in the SS group (p¼0.028).
Two of these patients needed extrarenal depuration measures. The other predictors of
CIN in the univariate analysis were the higher volume contrast used (217 vs 169 cc;
p¼0.021), the higher age (73.06 vs 62.01; p¼0.001) and the lower hemoglobin prior
the procedure (12.95 vs 14; p¼0.04). In the multivariate analysis, the only predictors
of CIN were the hydration (SS group): OR¼0.19 (0.05-0.69), p¼0.012 and the
contrast volume used: OR¼1.008 (1-1.015), p¼0.04.
Conclusions: Even having received higher doses of contrast, the patients who
received hydration during primary PCI (SS group), reduced by 53% the incidence of
CIN. Given the higher incidence of CIN in emergent procedures, and the morbidity
that it implies, we should improve prevention measures in these patients.
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Background: Entrapment of an intravascular ultrasonography (IVUS) catheter is
a rare but life-threatening complication of percutaneous coronary intervention (PCI).
There is a paucity of data on frequency and treatment of entrapment of an IVUS
catheter.
Methods: We retrospectively reviewed a total of 1852 consecutive patients (2096
lesions) who underwent PCI using 2351 stents (PtCr-EES, n ¼ 1224, 52.1%; BES n
¼ 749, 31.9%; CoCr-EES, n ¼ 148, 6.3%; ZES, n ¼ 92, 3.9%; SES, n ¼ 9, 3.8%;
PtCr-PES, n ¼ 5, 0.2%; BMS, n ¼ 124, 5.3%) in our hospital from June 2012 to
May 2013. Of those, we use an IVUS catheter in 1610 patients (87.1%, 1802
lesions). IVUS catheter included View IT (Terumo, n ¼ 1771, 98.3%), iLAB
(Boston Scientiﬁc, n ¼ 17, 0.9%), Volcano (Volcano, n¼ 8, 0.4%), and others (n ¼ 5,
0.3%).
Results: During the study period, entrapment of an IVUS catheter at the stented lesion
occurred in 10 lesions (0.6%, 13 stents). There was no signiﬁcant difference in the
stent (PtCr-EES n ¼ 10, BES n¼ 3) and IVUS catheter (View IT n ¼ 10). Of those,stracts/POSTER/PCI Complications B109
